Evidence map›Paper›PMID 24613276›Full record

ArticleCancer genetics

Acquired chromosomal anomalies in chronic lymphocytic leukemia patients compared with more than 50,000 quasi-normal participants.

Cathy C Laurie, Cecelia A Laurie, Stephanie A Smoley, Erin E Carlson, Ian Flinn, Brooke L Fridley, Harvey A Greisman, John G Gribben, Diane F Jelinek, Sarah C Nelson and 7 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Cathy C LaurieBiostatistics Department, University of Washington, Seattle, WA, USA. Electronic address: cclaurie@u.washington.edu.
Cecelia A LaurieBiostatistics Department, University of Washington, Seattle, WA, USA.
Stephanie A SmoleyDepartment of Laboratory Medicine and Pathology, Cytogenetics Laboratory, Mayo Clinic, Rochester, MN, USA.
Erin E CarlsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Ian FlinnSarah Cannon Research Institute, Nashville, TN, USA.
Brooke L FridleyDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; University of Kansas Medical Center, Kansas City, KS, USA.
Harvey A GreismanDepartment of Laboratory Medicine, University of Washington, Seattle, WA, USA; PhenoPath Laboratories, Seattle, WA, USA.
John G GribbenBarts Cancer Institute, Queen Mary, University of London, London, UK.
Diane F JelinekDivision of Hematology, Mayo Clinic, Rochester, MN, USA; Department of Immunology, Mayo Clinic, Rochester, MN, USA.
Sarah C NelsonBiostatistics Department, University of Washington, Seattle, WA, USA.
Elisabeth PaiettaThe North Division of Montefiore Medical Center, Bronx, NY, USA.
Dan SchaidDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Zhuoxin SunDepartment of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
Martin S TallmanMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Richard WeinshilboumDivision of Clinical Pharmacology, Mayo Clinic, Rochester, MN, USA.
Neil E KayDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
Tait D ShanafeltDivision of Hematology, Mayo Clinic, Rochester, MN, USA.
University of Washington · USMayo Clinic · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USQueen Mary University of London · GBMontefiore Medical Center · USSarah Cannon · USUniversity of Kansas Medical Center · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
ECOG OPERATIONS OFFICE (IBCSG)U10CA021115 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2013
$132.6M
Statistics CoreU10CA180794 · NCI · DANA-FARBER CANCER INST · PI PAUL J CATALANO, CONSTANTINE A. GATSONIS · 2014 to 2026
$111.2M
Tissue CoreP01CA081534 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIPPS, THOMAS J · 2000 to 2016
$59.5M
Psychosocial Influences on Rural Children's Oral HealthR01DE014899 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FOXMAN, BETSY, MARAZITA, MARY L. · 2002 to 2020
$39.9M
Foreign Accrual - ECOGU10CA037403 · NCI · UNIVERSITY OF WISCONSIN MADISON · PI COMIS, ROBERT L · 1985 to 2014
$34.6M
Extending the Phenotype of Nonsyndromic Orofacial CleftsR01DE016148 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MARAZITA, MARY L., WEINBERG, SETH M · 2004 to 2018
$19.7M
Pharmacogenetics of Phase II Drug Metabolizing EnzymesU19GM061388 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 2010 to 2014
$15.8M
ECOG Specimen BankingU24CA114737 · NCI · FRONTIER SCI &TECHNOLOGY RSCH FDN, INC · PI COMIS, ROBERT L · 2005 to 2014
$9.3M
Statistical Methods for X-Chromosome Genetic DataP01GM099568 · NIGMS · UNIVERSITY OF WASHINGTON · PI WEIR, BRUCE S. · 2012 to 2016
$7.3M
INHERITED VARIATIONS IN DRUG-METABOLIZING ENZYMESR01GM028157 · NIGMS · MAYO CLINIC ROCHESTER · PI WEINSHILBOUM, RICHARD M. · 1985 to 2019
$6.9M
Combination Therapy in B-Chronic Lymphocytic LeukemiaR01CA095241 · NCI · MAYO CLINIC ROCHESTER · PI KAY, NEIL E · 2002 to 2012
$5.7M
NCI NIH HHS CA114737NCI NIH HHS CA132780NCI NIH HHS CA21115NCI NIH HHS CA95241NCI NIH HHS P01 CA081534NCI NIH HHS P01-CA81538NCI NIH HHS P30 CA015083NCI NIH HHS R01 CA095241NCI NIH HHS R01 CA132780NCI NIH HHS R01 CA136591NCI NIH HHS R01-CA136591NCI NIH HHS R01 CA138461NCI NIH HHS R01-CA138461NCI NIH HHS U10 CA021115NCI NIH HHS U10-CA02115NCI NIH HHS U10 CA037403NCI NIH HHS U10 CA180794NCI NIH HHS U24 CA114737NHGRI NIH HHS U01 HG005137NHGRI NIH HHS U01-HG005137NHGRI NIH HHS U01 HG005157NHGRI NIH HHS U01-HG005157NICHD NIH HHS HD52953NICHD NIH HHS HD57192NICHD NIH HHS R01 HD052953NICHD NIH HHS R01 HD057192NIDCR NIH HHS R01 DE014899NIDCR NIH HHS R01-DE014899NIDCR NIH HHS R01 DE016148NIDCR NIH HHS R01-DE016148NIDCR NIH HHS U01 DE018903NIDCR NIH HHS U01-DE018903NIDCR NIH HHS U01 DE018993NIDCR NIH HHS U01-DE-018993NIGMS NIH HHS P01 GM099568NIGMS NIH HHS P01-GM099568NIGMS NIH HHS R01 GM028157NIGMS NIH HHS R01-GM28157NIGMS NIH HHS U19 GM061388NIGMS NIH HHS U19-GM61388
6 · The paper itself

Abstract

Pretherapy patients with chronic lymphocytic leukemia (CLL) from US Intergroup trial E2997 were analyzed with single nucleotide polymorphism microarrays to detect acquired chromosomal anomalies. The four CLL-typical anomalies (11q-, +12, 13q-, and 17p-) were found at expected frequencies. Acquired anomalies in other regions account for 70% of the total detected anomalies, and their number per participant has a significant effect on progression-free survival after adjusting for the effects of 17p- (and other covariates). These results were compared with those from a previous study of more than 50,000 participants from the GENEVA consortium of genome-wide association studies, which analyzed individuals with a variety of medical conditions and healthy controls. The percentage of individuals with acquired anomalies is vastly different between the two studies (GENEVA 0.8%; E2997 80%). The composition of the anomalies also differs, with GENEVA having a higher percentage of acquired uniparental disomies and a lower percentage of deletions. The four common CLL anomalies are among the most frequent in GENEVA participants, some of whom may have CLL-precursor conditions or early stages of CLL. However, the patients from E2997 (and other studies of symptomatic CLL) have recurrent acquired anomalies that were not found in GENEVA participants, thus identifying genomic changes that may be unique to symptomatic stages of CLL.

Indexed as

Chromosome AberrationsPolymorphism, Single NucleotideAdultAgedAged, 80 and overCase-Control StudiesChromosome DeletionChromosome DisordersChromosome MappingClinical Trials, Phase III as TopicFemaleGenome-Wide Association StudyGenotypeHumansIn Situ Hybridization, FluorescenceLeukemia, Lymphocytic, Chronic, B-Cellcancer precursor conditionChromosomal aberrationchromosomal mosaicchronic lymphocytic leukemiacytogenetics

Identifiers

PMID24613276
PMCPMC4074414
OpenAlexW2068719985

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.